What Do Analysts Think About Royalty Pharma Plc (RPRX)?
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most profitable biotech stocks to buy.
Repros Therapeutics Inc. (RPRX)
This company is not actively trading or the ticker does belong to another company in our database now. The symbol (RPRX) is currently associated with the following stock: Royalty Pharma Plc (RPRX)
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.60 | 20,000 | $32,000.00 | 107,422 | 2016-12-09 | Filing | |
| $0.93 | 10,000 | $9,300.00 | 87,422 | 2016-02-18 | Filing | |
| $1.11 | 8,400 | $9,324.00 | 10,000 | 2016-01-25 | Filing | |
| $1.13 | 980 | $1,107.40 | 1,600 | 2016-01-25 | Filing | |
| $1.12 | 620 | $694.40 | 620 | 2016-01-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.95 | 3,305 | $6,444.75 | 0 | 2016-11-21 | Filing | |
| $0.65 | 76,703 | $50,202.11 | 2,552,233 | 2009-12-21 | Filing | |
| $0.68 | 30,000 | $20,280.00 | 2,628,936 | 2009-12-18 | Filing | |
| $0.70 | 50,100 | $35,220.30 | 2,658,936 | 2009-12-17 | Filing | |
| $0.67 | 181,700 | $121,739.00 | 2,709,036 | 2009-12-15 | Filing |
Institutional Investors' Holdings
News See All
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth
Royalty Pharma plc (NASDAQ:RPRX), a leader in biopharma royalties, made major strategic moves in September 2025.
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United States down to "most favored...
TD Cowen Maintains a Buy on Royalty Pharma (RPRX)
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best affordable biotech stocks to invest in now. On September 12, TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Royalty Pharma Plc (NASDAQ...
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in acquiring and managing royalties from marketed drugs, continues to demonstrate strong growth and strategic expansion.
12 Cheap Healthcare Stocks to Buy Now
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there are any opportunities ...
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program
Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Hedge Fund Resource Center Billionaire Hedge Funds
